INVIVYD, INC. (IVVD) Spending and interest coverage
- R&D / revenue · 12 months: Value 133.97%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 19.24%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 133.97% | Research and development expense / revenue. Period ending 2026-06-30. $78.19M ÷ $58.37M × 100 ≈ 133.97% |
| Stock-based compensation / revenue · 12 months | 19.24% | Share-based compensation / revenue. Period ending 2026-06-30. $11.23M ÷ $58.37M × 100 ≈ 19.24% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 78.19M USD | Research and Development Expense |
| Revenue | 58.37M USD | |
| Stock-based compensation | 11.23M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -112.53M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $78.19M | $58.37M | $11.23M | $-112.53M | (m) | 133.97% | 19.24% | (m) | (m) |
| 2026-03-31 | $58.40M | $55.87M | $11.51M | $-81.77M | (m) | 104.53% | 20.61% | (m) | (m) |
| 2025-12-31 | $38.31M | $53.43M | $11.64M | $-55.56M | (m) | 71.70% | 21.79% | (m) | (m) |
| 2025-09-30 | $46.17M | $50.04M | $12.14M | $-62.23M | (m) | 92.27% | 24.25% | (m) | (m) |
| 2025-06-30 | $95.97M | $46.21M | $11.93M | $-113.52M | (m) | 207.69% | 25.81% | (m) | (m) |
| 2025-03-31 | $116.73M | $36.69M | $17.23M | $-147.71M | (m) | 318.18% | 46.98% | (m) | (m) |
| 2024-12-31 | $137.25M | $25.38M | $19.79M | $-176.88M | (m) | 540.71% | 77.95% | (m) | (m) |
| 2024-09-30 | $181.61M | (m) | $21.07M | $-234.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $149.33M | (m) | $22.48M | $-215.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $162.62M | (m) | $18.66M | $-219.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $158.66M | (m) | $18.68M | $-212.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $116.31M | (m) | $20.25M | $-184.22M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $120.87M | (m) | $23.38M | $-188.49M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $114.38M | (m) | $25.07M | $-186.36M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $179.21M | (m) | $21.65M | $-248.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $227.72M | (m) | $23.60M | $-282.91M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $242.85M | (m) | $22.18M | $-296.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $240.89M | (m) | $19.16M | $-288.94M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $182.89M | (m) | $17.76M | $-226.91M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |